Analyst Research Report Snapshot

Title:

BAVARIAN NORDIC - CANCER IMMUNOTHERAPY PRIORITIES DEFINED

Price:

$10.00

Provider:

Edison Investment Research

Date:

18 Nov 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

BAVA.CO

Available for Immediate Download
Summary:

Bavarian Nordic has completed its cancer immunotherapy portfolio assessment and has confirmed that CV-301will be prioritised in colorectal cancer (CRC). Prostvac, its lead prostate vaccine, remains the key value driver for the company. Regulatory discussions are taking place to determine the design of larger randomised placebo controlled trials to evaluate CV-301’s potential in the CRC setting, subject to securing funding/partnership. Prostvac development progress remains on track: enrolment in the Phase III PROSPECT trial should complete in H114, and two Phase II combination studies with enzalutamide are also underway.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.